Venous thromboembolism (VTE) is an increasingly recognized problem in the post-hematopoietic stem cell transplantation (HSCT) setting, with a lack of high-quality evidence-based data to recommend best practices. Few patients with hematologic malignancies and even fewer post-HSCT patients were included in randomized trials of VTE prophylaxis and treatment. Prior VTE, GVHD, infections and indwelling venous catheters are risk factors for thrombosis. The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT. These patients are also at high risk of bleeding complications because of prolonged thrombocytopenia and managing the competing risks of bleeding and thrombosis can be challenging. This review aims to provide a practical, clinician-focused approach to the prevention and treatment of VTE in the post-HSCT setting.
INTRODUCTION
The association between malignancy and thromboembolic disease is well established. [1] [2] In addition to increased prevalence in patients with cancer, venous thromboembolism (VTE) has been identified as an independent predictor of reduced survival in these patients. [3] [4] [5] Although most commonly associated with solid malignancies, VTE is increasingly recognized as a complication in patients with hematologic malignancies and various studies have reported rates of VTE as high as 6% in patients with lymphoma, 6 ,7 5-20% in patients with acute leukemia 8, 9 and 5-10% in multiple myeloma (MM) that can increase to as high as 23-75% in patients treated with chemotherapy, thalidomide or lenalidomide, and dexamethasone. 10, 11 A large number of patients with hematologic malignancies undergo hematopoietic stem cell transplantation (HSCT); however, there is limited information regarding the incidence, risk factors, and the optimal approach to prevention and treatment of VTE in these patients. A 3.7% 1-year incidence of VTE, and 8-20% incidence of catheter-related thrombosis (CRT) have been reported in autologous stem cell transplant recipients. 12 HSCT recipients have several identifiable risk factors for thrombosis including malignancy, high-dose myeloablative chemotherapy and immune-modulatory drugs, [13] [14] [15] [16] graft versus host disease (GVHD), [17] [18] [19] infections, 14, 20 indwelling vascular catheters and prolonged immobilization.
14 HSCT is also associated with an 'acquired hypercoagulable state' characterized by inflammation, endothelial damage and activation of endothelium-dependent coagulation factors, increase in von Willebrand factor and platelet adhesion, increased thrombin generation, decreased anti-thrombin levels and decreased levels of anticoagulant proteins such as protein C. [21] [22] [23] [24] [25] [26] [27] graft versus host disease (GVHD) is associated with inflammation that leads to endothelial damage and activation. 28 TNF alpha, an essential mediator in the pathogenesis of GVHD, has been shown to enhance pro-thrombotic alterations on the endothelial cell surface. 29 
INCIDENCE AND RISK FACTORS FOR VTE AFTER HSCT
Retrospective studies of venous thromboembolic complications in HSCT recipients report a high incidence of VTE, as well as bleeding complications. [17] [18] [19] 30, 31 In an analysis of 1514 patients undergoing HSCT as inpatients and followed for 180 days, Gerber et al. 17 reported a 4.6% incidence of VTE, the majority of which were catheter related and all of which occurred after engraftment. Another retrospective series of 447 patients undergoing bone marrow transplantation reported a 5.7% incidence of VTE in the first 100 days following transplant despite being on heparin prophylaxis (100 U/kg IV daily) for hepatic sinusoidal obstruction syndrome. 18 A retrospective study by O'Hara et al. 31 from Indiana University found a 2.5% incidence of VTE in patients undergoing autologous HSCT, however, large proportion of patients in this study underwent HSCT for germ cell tumors and not hematologic conditions. Finally, Gonsalves et al. 30 investigated the incidence of symptomatic VTE after HSCT in an ambulatory care setting and found a 1-year incidence of 3.7%. These studies reported that VTE occurred more frequently following allogenic HSCT, in patients with a history of previous VTE or those with GVHD. 19, 31 Most episodes of VTE in these studies were catheter related. Cortolezzi et al. 32 have previously reported that there was a 12% incidence of catheter-related thromboembolic complications in a cohort of 416 patients with hematologic malignancies. Twenty-one percent of these patients were HSCT recipients and 81.2% had platelet counts o 50 000/μL. There was a non-statistically significant trend toward lower rates of thrombotic complications with thrombocytopenia. 32 GVHD has also been identified as a risk factor for VTE, [17] [18] [19] which has been attributed to the inflammatory milieu and endothelial activation. 28, 29 In addition, some patients with GVH are treated with extracorporeal photopheresis that necessitates placement of a central venous 1 catheter (CVC) for prolonged periods. This is a potential risk factor for thrombosis which has been reported as a reason for discontinuation of therapy. 33, 34 In addition to a risk of thrombosis, HSCT recipients also have an increased risk of bleeding because of prolonged and severe thrombocytopenia. In the studies mentioned above, the rate of bleeding in HSCT recipients ranges from 15.2 to 27.1%, and life-threatening or fatal bleeding occurred in 1.1-3.6% patients. [17] [18] [19] Gerber et al. 17 reported that the initiation of therapeutic anticoagulation during days 1-180 after HSCT was the strongest predictor of bleeding (odds ratio (OR) 3 17 Given the competing risks of bleeding and thrombosis, identifying patients at high risk for these outcomes can be used to optimize strategies for VTE prophylaxis. Previous VTE is a well-recognized risk factor for VTE that may help target prophylaxis. 35, 36 GVHD, although associated with thrombosis, is less useful as it is also associated with an increased risk of bleeding. The timing of hemostatic complications is also an important consideration as bleeding events are more likely to occur early in the post-transplant course when patients are profoundly thrombocytopenic, whereas thrombotic events occur more frequently after hematopoietic recovery. 17, 19 It must be noted that prolonged hospitalization, common in the HSCT setting, is a known risk factor for VTE. 37 This association has not been extensively studied in the HSCT population; however, one study comparing outcomes of brief (o 5 days) and prolonged (45 days) in patients undergoing autologous HSCT for MM noted a non-statistically significant increased rate of thrombosis in patients with prolonged hospitalizations (3.7% vs 4.6%). 38 Inherited thombophilias (for example, factor V Leiden, prothrombin gene mutation, protein C or S deficiency) are associated with an increased risk of thrombosis in the general population. 37 In the HSCT population, one prospective study of 171 patients suggested that there is a disproportionate prevalence of inherited thrombophilia in patients with central line-associated thrombosis, 39 while a second study found no correlation between inherited thrombophilias and thrombotic events in HSCT recipients. 40 An inherited thrombophilia may add some risk in patients who already have an underlying malignancy, indwelling catheters and often prolonged hospitalizations.
CATHETER-RELATED THROMBOSIS
CRT is a common problem with asymptomatic thrombosis occurring in 19-41%, and symptomatic thrombosis in 1-4% of patients. 41 CRT can lead to significant discomfort from symptoms, catheter dysfunction, increased risk for infections and long-term risk for venous stenosis. 41 Although CRT clearly contributes to morbidity and catheter dysfunction, the majority of CRT are asymptomatic and there is little evidence that CRT is associated with an increased rate of pulmonary embolism or increased mortality. 42 The primary objectives of treatment of CRT are to reduce symptoms, prevent extension into more central veins, preserve access and to prevent chronic venous stenosis. There is no evidence that removal of the catheter improves outcomes. 43, 44 Therefore, it is reasonable to not remove the catheter unless it is non-functional, no longer needed or may be infected. There are no prospective randomized studies of thrombolysis for CRT, however, thrombus reduction by catheter-directed thrombolysis is relatively safe and effective and may be tried in an attempt to preserve the catheter. 45, 46 Anticoagulation is required in patients with acute CRT regardless of whether the catheter is removed. 47, 48 We prefer low molecular weight heparin (LMWH) as there is evidence of its effectiveness in other patients with cancer-related VTE. Vitamin K antagonists may be used if LMWH is contraindicated. In a prospective study of 78 patients with CRT treated with full-dose dalteparin bridged to warfarin, there were no new thrombotic events at 3 months and 57% of catheters were still functional. 49 The optimum duration of anticoagulation has not been evaluated in prospective studies. Current American College of Chest Physicians (ACCP) guidelines recommend anticoagulation for 3 months or until the catheter is removed, whichever is longer. 48 Several clinicians prefer to continue anticoagulation for 1-2 weeks after the catheter is removed. 41 
VTE PROPHYLAXIS
There are currently no studies of empiric prophylactic anticoagulation in HSCT recipients. In the absence of HSCT-specific studies, studies in patients with cancer provide the next best evidence that can be extrapolated. Two large studies of prophylactic anticoagulation in patients with cancer undergoing chemotherapy, the PROTECHT (nadroparin vs placebo) and SAVE-ONCO (semuloparin vs placebo) trials showed a significant reduction in the relative risk of VTE with anticoagulation, however, the absolute risk reduction is small and no survival benefit has been demonstrated. 50, 51 The American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines advise against the use of routine prophylactic anticoagulation in ambulatory patients with cancer. 47, 52 An exception is made for patients with MM receiving treatment with thalidomide, lenalidomide or pomalidomide. Hospitalized patients and those with CVCs are also at higher risk of thrombosis. 53 These special situations are addressed below.
Multiple myeloma
Patients with MM have a high baseline risk of thrombosis of 5-10% that increases to 23-75% in patients being treated with the immunomodulators thalidomide and lenalidomide with dexamethasone or chemotherapy. 10, 11 Consolidation therapy with the thalidomide or lenalidomide after HSCT has been shown to improve complete respose rates and prolong event-free survival and is thus rapidly becoming standard of care. 54, 55 In patients receiving thalidomide consolidation after autologous stem cell transplantation for MM, Barlogie et al. 54 reported that rate of VTE was 24% and 6% in the induction and consolidation periods, respectively, despite thromboprophylaxis with LMWH. McCarthy et al. 55 reported that there were no episodes of VTE in patients receiving consolidation therapy with lenalidomide, however, these patients were also getting prophylactic anticoagulation. Although pomalidomide has not been evaluated in the setting of consolidation after autologous HSCT, a 2% to 4% rate of VTE with thromboprophylaxis has been reported in the setting of relapsed/ refractory myeloma. [56] [57] [58] Thromboprophylaxis strategies have not been specifically evaluated in patients on maintenance therapy with novel immune-modulatory agents after transplant, however, studies in patients with newly diagnosed MM receiving lenalidomide or thalidomide-based treatments show a significant benefit of thromboprophylaxis. 59, 60 Palumbo et al. 59 randomly assigned 659 patients receiving thalidomide-based regimens to low-dose aspirin, warfarin or enoxaparin. The rate of VTE, serious cardiovascular events or sudden cardiac death in the first 6 months was 6.4% in the aspirin group, 8.2% in the warfarin group and 5% in the enoxaparin group, whereas there were three major bleeding episodes, all in the aspirin group. The risk of VTE in the aspirin and enoxaparin groups was not different. In a second study evaluating aspirin vs LMWH prophylaxis, 342 patients on lenalidomide-based regimens were randomized to low-dose aspirin or prophylactic LMWH. No major hemorrhagic complications were reported. Symptomatic VTE was reported in 2.3% patients in the aspirin group and 1.2% in the LMWH group. Compared with LMWH, the absolute difference in the proportion of VTE was 1.07% (95% CI, − 1.69 to 3.83; P = 0.452) in the ASA group. 60 Therefore, ASA may be an effective and less-expensive alternative to LMWH thromboprophylaxis in low-risk patients. The International Myeloma Working group and ASCO recommend prophylaxis with either aspirin or LMWH for lower risk patients, and LMWH for higher risk patients receiving thalidomide or lenalidomide. 47, 61 Hospitalized patients Based on randomized clinical trials of thromboprophylaxis in medically ill hospitalized patients, 62, 63 and a meta-analysis that demonstrated 40% lower rates of VTE with pharmacologic prophylaxis versus placebo, 64 the current ACCP 52 and ASCO guidelines 47 strongly recommend thromboprophylaxis in hospitalized medically ill and cancer patients, respectively. However, trials of thromboprophylaxis did not include HSCT patients who are not specifically included in these recommendations. The potential benefit from VTE prophylaxis is proportional to VTE risk and therefore this is particularly important in patients with reduced mobility, and with a history of VTE (if not on long-term anticoagulation) because of an even higher risk of thrombosis. Our practice is to start prophylactic anticoagulation for hospitalized patients in the post-transplant period once the platelet count is 450 000/μL, and there is no active bleeding. For very high-risk patients, anticoagulation can be considered if the platelet count is 430 000/μL, however, this must be balanced with the risk of bleeding.
Central venous catheters
There is an emerging trend toward increasing ambulatory care and 'outpatient transplants' in HSCT patients, in contrast with a more traditional model where patients remained hospitalized for most of the post-transplant course. Ambulatory HSCT patients frequently have indwelling vascular catheters with the potential for developing CRT. Incidence of symptomatic CRT ranges from 4 to 14% in different studies. 41 Despite multiple randomized and observational studies, thromboprophylaxis for the prevention of CRT in patients with cancer remains controversial. A randomized control trial of enoxaparin 40 mg SC daily for 6 weeks vs placebo daily for 6 weeks in patients with cancer undergoing CVC insertion found that enoxaparin was safe, but did not reduce the rate of CVC-related thrombosis. 45 The largest study of thromboprophylaxis in CVC randomized 1590 cancer patients undergoing chemotherapy to adjusted-dose warfarin (international normalized ratio, 1.5-2.0), fixed-dose warfarin (1 mg/d) and no prophylaxis. 65 Symptomatic CRT was less frequent in the patients given adjusted-dose warfarin than in those who received no prophylaxis (2.7% vs 5.9%, P = 0.019), but major bleeding was more common (3.4% vs 0.2%, P o0.001). Warfarin 1 mg/d was not protective but was still associated with increased risk of major bleeding. 65 Three recent meta-analyses of randomized trials concluded that prophylactic warfarin and LMWH do not significantly reduce symptomatic CRT in patients with cancer. [66] [67] [68] Based on the available evidence, prophylactic anticoagulation to prevent CRT is not routinely recommended. 41 VTE TREATMENT Venous duplex ultrasonography should be performed in patients presenting with extremity swelling, redness or tenderness; or pulmonary angiography in patients with chest pain, dyspnea or unexplained tachycardia. A clinical assessment of bleeding risk is 
Treatment

General principles
Start therapeutic doses of LMWH or IV UFH in patients who have platelet count 450 000/μL and no active bleeding. UFH is preferred in case of renal impairment (GFR o30 mL/min) or high bleeding risk. Continue LMWH or transition to warfarin (if LMWH is contraindicated) for maintenance therapy. DOACs are not recommended in patients with cancer.
Duration of anticoagulation
General: 3-6 months or as long as malignancy or use of IMiDs persists, whichever is longer. Catheter-related thrombosis: 3 months or as long as catheter is in place.
Inferior vena cava filters
Restrict use to patients in whom anticoagulation is contraindicated, or those who develop pulmonary embolism on anticoagulation. Remove as soon as anticoagulation can be started.
Abbreviations: DOACs = direct oral anticoagulants; IMiDs = immunomodulatory drugs; LMWH = low molecular weight heparin; MM = multiple myeloma; UFH = unfractionated heparin. 69 There is a need for trials evaluating the use of direct oral anticoagulants in patients with cancer and HSCT. Based on current evidence, their use cannot be recommended outside of a research setting.
The use of inferior vena cava filters should be restricted to patients with acute deep vein thrombosis and a contraindication to anticoagulation, and possibly patients who develop pulmonary embolism while on therapeutic anticoagulation. 48 Filters should not be used for primary prophylaxis of pulmonary embolism. [70] [71] [72] Retrievable filters should be removed as soon as risk of pulmonary embolism resolves or when anticoagulation can be resumed. These recommendations are in keeping with the 2012 ACCP guidelines and the ASH choosing wisely campaign. 47, 72 In patients with large, symptomatic thrombosis and severe thrombocytopenia, we sometimes follow a strategy of platelet transfusions to reach a threshold of 50 000/μL to allow safer anticoagulation with heparin. There is little evidence to support this and the decision must be individualized.
The optimal duration of anticoagulation for VTE in HSCT patients has not been evaluated in prospective studies. The recommendation for patients with cancer-related VTE is anticoagulation for 3-6 months, with ongoing therapy if the malignancy persists. 47, 48 We follow an analogous strategy in HSCT patients with the caveat that extended anticoagulation is often not feasible in patients with relapsed disease and a high likelihood of disease-related or treatment-related thrombocytopenia.
INCIDENTAL VTE
The widespread use of multislice multidetector-row computed tomography scanning has led to the emerging issue of clinically asymptomatic, incidentally diagnosed pulmonary embolism and deep vein thrombosis. 73, 74 These 'asymptomatic' or 'unsuspected' VTE are commonly known as 'incidental' pulmonary embolism as recommended by the International Society of Thrombosis and Hemostasis. 75 Although the natural history and outcomes of incidental VTE are not clearly known, some reports suggest that these events may be related to a higher rate of recurrent VTE, hemorrhage and death similar to symptomatic VTE. 76, 77 For example, den Exeter et al. 76 reported a 13.3% recurrence rate of incidental VTE in the first year after diagnosis. Several studies have also reported an association of VTE, both symptomatic and incidental, with poorer survival in patients with cancer. 3, 4, [77] [78] [79] This may be a less important consideration in HSCT recipients, especially those maintained in remission. In the absence of studies that justify withholding anticoagulation in patients with incidental VTE, the 2012 ACCP guidelines recommend treating incidental VTE in a manner identical to symptomatic VTE with fulldose anticoagulation for at least 3-6 months, and longer in the presence of persistent or recurrent cancer. 47 Full-dose LMWH, or unfractionated heparin transitioned to warfarin (when LMWH is contraindicated) may be used. We do not recommend treating patients with active cancer with direct oral anticoagulants outside of a clinical trial. CONCLUSIONS VTE is an increasingly recognized problem in patients with hematologic malignancies, including HSCT patients, however, these patients are also at risk of potentially life-threatening bleeding complications complicating VTE prevention and treatment strategies. Pharmacologic prophylaxis is indicated in patients on lenalidomide (or other immunomodulatory agent) consolidation therapy after HSCT, and should be considered in patients with a history of VTE. We recommend treating symptomatic or incidental VTE with full-dose anticoagulation for at least 3 months or longer in the presence of active cancer. Central venous CRT may be treated with full-dose anticoagulation and does not always necessitate removal of the catheter (Table 1) . There is an urgent need for well-designed clinical studies of VTE prevention and treatment in HSCT patients.
